Who Cannot Take a GLP-1: What the Label Forbids, and What It Only Warns About

5 min read · doses off DailyMed · last verified November 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

People use the word contraindication loosely, and these labels do not. We checked Section 4 of the Wegovy, Zepbound and Ozempic prescribing information, and each one contains exactly two entries.

What the label actually forbids

What the label actually forbids
WhoWhy
Anyone with medullary thyroid carcinoma in their own or their family's history, or with MEN 2 This is the boxed warning. Rodents given semaglutide, tirzepatide or liraglutide developed thyroid C-cell tumors in a way that tracked dose and duration. Whether that carries over to people has never been settled — and the labels resolve the uncertainty by ruling these patients out rather than monitoring them.
Anyone in whom this drug, or an ingredient of it, has already provoked a serious hypersensitivity reaction Anaphylaxis and angioedema have both been reported. Reacting to one drug in the class does not automatically mean reacting to another, but it is a question for an allergist before any switch rather than a matter to find out by trying.

That is the whole list. Anyone starting one of these drugs should be told the signs of a thyroid tumor (a lump in the neck, trouble swallowing, a voice that stays hoarse) and reminded at follow-ups.

Two things commonly called contraindications that are not

Both matter, but neither appears in Section 4, and that changes the question you bring to your prescriber.

  • Type 1 diabetes. The labels for Ozempic and Mounjaro cover type 2 only, so using them in type 1 is outside the approved indication, which is not the same as being forbidden. The current Mounjaro and Zepbound labels do not mention type 1 at all. The caution still has substance. These drugs do not replace insulin, and ketoacidosis has occurred where they were treated as if they did.
  • Pregnancy. This sits in the section on specific populations, not with the prohibitions. The weight-loss labels (Wegovy, Zepbound, Saxenda) tell you to stop once you know you are pregnant, and semaglutide's labels say to stop two months before a planned one. The diabetes labels (Ozempic, Mounjaro) instead allow use in pregnancy where the expected benefit outweighs the possible harm to the fetus, as does Wegovy's for MASH. These are strong instructions, but they are a different kind of statement from the two above. If exposure happens by accident, call your obstetric team; there is no need to panic.

Where real caution belongs

None of these is an absolute bar. They come from the label warnings and from clinical judgment, and several of them will still be the reason a sensible prescriber says no.

  • A previous episode of pancreatitis. The labels warn about it without prohibiting the drug, but most prescribers steer away after a documented episode. Severe pain that persists means stopping and ruling it out before anything restarts.
  • Severe gastroparesis or serious existing gut disease. These drugs slow the stomach deliberately. Adding that to a stomach already emptying badly produces symptoms people cannot live with and a real hazard under anesthesia.
  • Known gallstones or active gallbladder disease. Losing weight quickly promotes gallstones, and the labels carry gallbladder warnings of their own. New pain under the right ribs needs imaging rather than reassurance.
  • Diabetic retinopathy, particularly on insulin. Bringing blood sugar down fast can briefly worsen retinopathy, and the effect tracked the size of the drop. A dilated eye exam beforehand is reasonable.
  • A history of restrictive eating disorder. No label mentions it, and it may be the most important item here. A drug whose entire mechanism is appetite suppression sits directly on top of that pathology.
  • Mood and suicidality. In January 2026 the FDA asked for the suicidal behavior and ideation warning to come off the Wegovy, Zepbound and Saxenda labels after its review found no elevated risk, and those labels no longer carry it. The FDA still wants any fresh or deepening low mood, any thought of suicide, or any odd shift in mood or behavior raised with your clinician.
  • Advanced kidney disease. Kidney function does not bar these drugs, but data thin out below an eGFR of 30. The real danger is dehydration from vomiting or diarrhea, and weak kidneys have the least margin for it.
  • Previous bariatric surgery. Rearranged anatomy changes how these drugs behave, in both directions. GLP-1s are often used after weight regain, with careful titration.

Things that should not be taken alongside

  • Another GLP-1. Never two at once; one stops before the next begins.
  • A DPP-4 inhibitor such as Januvia or Tradjenta. It works on the same pathway and adds nothing.
  • Insulin or a sulfonylurea without reducing them first. This is the main route to a dangerous hypo on these drugs.
  • The contraceptive pill, unsupported. Tirzepatide's label wants something other than a swallowed pill, or a barrier alongside it, across four weeks from the start and again after every increase.
  • Drugs with a narrow margin (levothyroxine, warfarin, anti-epileptics, digoxin). A stomach that empties more slowly changes absorption, so levels and INR deserve closer watching for the first couple of months and after each step up.

Particular groups

  • Children and teenagers. Wegovy and Saxenda from 12, Trulicity and Mounjaro from 10 for type 2 diabetes. The adult-only list runs Ozempic, Zepbound, Rybelsus, Foundayo. Compounded products have no pediatric data at all.
  • Older adults. There is no dose change for age itself, but older adults are more vulnerable to dehydration, and to hypos when a GLP-1 is stacked on insulin. Start low, climb slowly, and think about falls if someone goes light-headed standing up.
  • People below the BMI thresholds the trials used. Below a BMI of 27 with a related condition, or 30 without, the balance of benefit and risk has not been established. Use for appearance or performance is off-label.
  • Anyone underweight, or losing weight without meaning to. Do not start. Suppressing appetite further risks malnutrition and muscle loss, and may hide the real cause of the weight loss.

What this does not cover

This page covers the class as a whole. Every product has its own warnings, and the label for the drug you were prescribed is the document that governs. Compounded products carry a separate set of concerns around sterility, identity and dosing errors that no FDA label addresses. Surgery holds and pregnancy washouts each have their own page.

Where to go next

References

  1. 1.U.S. National Library of Medicine — DailyMed. OZEMPIC (semaglutide) — SPL. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  2. 2.U.S. National Library of Medicine — DailyMed. MOUNJARO (tirzepatide) — SPL. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  3. 3.U.S. National Library of Medicine — DailyMed. WEGOVY (semaglutide) — SPL. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  4. 4.U.S. National Library of Medicine — DailyMed. ZEPBOUND (tirzepatide) — SPL. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  5. 5.U.S. National Library of Medicine — DailyMed. SAXENDA (liraglutide) — SPL. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
  6. 6.U.S. National Library of Medicine — DailyMed. TRULICITY (dulaglutide) — SPL. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
  7. 7.U.S. Food and Drug Administration. FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. Drug Safety Communication, January 13, 2026. FDA. 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp

Frequently Asked Questions

The contraindications section of the Wegovy, Zepbound and Ozempic labels contains two entries and no more: anyone with medullary thyroid carcinoma in their own or their family's history or with MEN 2, and anyone in whom the drug or an ingredient has already provoked a serious hypersensitivity reaction. Plenty of other situations call for caution, but those two are the only outright bars the labels state.
Not technically. These drugs are approved for type 2, so use in type 1 falls outside the indication; the contraindications section does not prohibit it. The caution behind it is real, though. A GLP-1 does not replace insulin, and ketoacidosis has resulted where it was treated as though it could.
The labels warn about pancreatitis rather than forbidding the drug to anyone who has had it, but most prescribers avoid it after a documented episode, and that is reasonable, not overcautious. If severe abdominal pain develops, especially reaching through to the back, the drug stops and pancreatitis is ruled out before anything resumes.
They can. Tirzepatide's label wants pill users on a method that is not swallowed, or paired with a barrier method, across four weeks from the start and four from each increase. A full climb from 2.5 to 15 mg is a start plus five increases, so six separate windows, not one. Anything not swallowed, such as a coil, implant, injection, patch or ring, is unaffected.
Not as a weight-loss treatment. The Wegovy, Zepbound and Saxenda labels tell you to stop as soon as you know you are pregnant; the diabetes labels (Ozempic, Mounjaro) allow use in pregnancy where the expected benefit outweighs the possible harm to the fetus. This appears under use in specific populations, not in the contraindications, so an accidental exposure is a reason to contact your obstetric team promptly, not to panic. Semaglutide's labels ask for two months' clearance before a planned pregnancy.

Editorial reference content, not medical advice. Changing a dose, holding one, or stopping altogether is a decision for you and your prescriber together. As for the numbers: we checked every dose figure here against the FDA-approved Structured Product Label on DailyMed in November 2026.

Browse all cheat sheets, top-N research lists, or long-form research deep-dives.